WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Chinese censors give Fight Club movie a new ending where police winKing Charles leaves hospital as Kate recovers at homeChinese censors give Fight Club movie a new ending where police winFarmers selling stock, land as 'extreme' drought dries up streamsEye watering amount of money for south Auckland roading project, cyclists sayTravel influencer reveals genius hack for getting toddlers to sleep on flights Now THAT'S a holiday photo album: Couple who sold everything they own to travel share 15 jawPictured: Twelve jaw'Free from selfMore toll roads coming, but at what price?
2.8111s , 6497.5703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Glance news portal